Neuroprotective Effects of OMO within the Hippocampus and Cortex in a D-Galactose and Aβ25–35-Induced Rat Model of Alzheimer’s Disease
Joint Authors
Lu, Hongmei
Deng, Shaodong
Chi, Honggang
Ye, Haiyi
Li, Xiao
Wang, Ying
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-14, 14 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-10-10
Country of Publication
Egypt
No. of Pages
14
Main Subjects
Abstract EN
Morinda officinalis F.C.
How.
(Rubiaceae) is a herbal medicine.
It has been recorded that its oligosaccharides have neuroprotective properties.
In order to understand the oligosaccharides extracted from Morinda officinalis (OMO), a systematic study was conducted to provide evidence that supports its use in neuroprotective therapies for Alzheimer’s disease (AD).
AD rat models were prepared with D-galactose and Aβ25–35.
The following groups were used in the present experiment: normal control group, sham-operated group, model group, Aricept group, OMO low-dose group, OMO medium-dose group, and OMO high-dose group.
The effects on behavioral tests, antioxidant levels, energy metabolism, neurotransmitter levels, and AD-related proteins were detected with corresponding methodologies.
AD rats administered with different doses of OMO all exhibited a significant (P<0.05) decrease in latency and an increase (P<0.05) in the ratio of swimming distance to total distance in a dose-dependent manner in the Morris water maze.
There was a significant (P<0.05) increase in antioxidant enzyme activities (SOD, GSH-Px, and CAT), neurotransmitter levels (acetylcholine, γ-GABA, and NE and DA), energy metabolism (Na+/K+-ATPase), and relative synaptophysin (SYP) expression levels in AD rats administered with OMO.
Furthermore, there was a significant (P<0.05) decrease in MDA levels and relative expression levels of APP, tau, and caspase-3 in AD rats with OMO.
The present research suggests that OMO protects against D-galactose and Aβ25–35-induced neurodegeneration, which may provide a novel strategy for improving AD in clinic.
American Psychological Association (APA)
Deng, Shaodong& Lu, Hongmei& Chi, Honggang& Wang, Ying& Li, Xiao& Ye, Haiyi. 2020. Neuroprotective Effects of OMO within the Hippocampus and Cortex in a D-Galactose and Aβ25–35-Induced Rat Model of Alzheimer’s Disease. Evidence-Based Complementary and Alternative Medicine،Vol. 2020, no. 2020, pp.1-14.
https://search.emarefa.net/detail/BIM-1154735
Modern Language Association (MLA)
Deng, Shaodong…[et al.]. Neuroprotective Effects of OMO within the Hippocampus and Cortex in a D-Galactose and Aβ25–35-Induced Rat Model of Alzheimer’s Disease. Evidence-Based Complementary and Alternative Medicine No. 2020 (2020), pp.1-14.
https://search.emarefa.net/detail/BIM-1154735
American Medical Association (AMA)
Deng, Shaodong& Lu, Hongmei& Chi, Honggang& Wang, Ying& Li, Xiao& Ye, Haiyi. Neuroprotective Effects of OMO within the Hippocampus and Cortex in a D-Galactose and Aβ25–35-Induced Rat Model of Alzheimer’s Disease. Evidence-Based Complementary and Alternative Medicine. 2020. Vol. 2020, no. 2020, pp.1-14.
https://search.emarefa.net/detail/BIM-1154735
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1154735